



Clinical Trials of tACS in Psychiatry

Flavio Frohlich

University of North Carolina - Chapel Hill

Department of Psychiatry

Department of Cell Biology and Physiology

Department of Biomedical Engineering

Department of Neurology


Neuroscience Center





Conflicts of Interest

- UNC owns IP related with FF as the lead inventor.
- UNC has determined the absence of a conflict of interest (COI) for the majority of work presented here and has determined a "COI with administrative considerations" for the clinical trials in the Frohlich Lab.
- FF is the founder, chief scientific officer, and majority owner of Pulvinar Neuro LLC. We provide solutions for transcranial current stimulation research.
- I speak with many companies and have received industry funding from Tal Medical (travel + research).
- I frequently travel and give presentations. I typically receive reimbursement and a stipend.



PULVINAR NEURO

NEUROTECHNOLOGY FOR THE FUTURE



RATIONAL DESIGN

Target Identification

Target Engagement Target Validation










FIGURE 1. Effect of Active and Sham Transcranial Direct-Current Stimulation (tDCS) on the Severity of Auditory Verbal Hallucinations^a





Neuron Review



Neuronal Dynamics and Neuropsychiatric Disorders: Toward a Translational Paradigm for Dysfunctional Large-Scale Networks

Peter J. Uhlhaas1,2,3,* and Wolf Singer1,2,4

¹Department of Neurophysiology, Max Planck Institute for Brain Research, Deutschordenstr. 46, Frankfurt am Main, 60528, Germany ²Ernst Strüngmann Institute (ESI) for Neuroscience, in Cooperation with Max Planck Society, Deutschordenstr. 46, Frankfurt am Main, 60528, Germany

Institute of Neuroscience and Psychology, University of Glasgow, 58 Hillhead Street, Glasgow G12 8QB, UK

Frankfurt Institute for Advanced Studies, Johann Wolfgang Goethe University, Ruth-Moufang-Str. 1, Frankfurt am Main, 60438, Germany


*Correspondence: peter.uhlhaas@glasgow.ac.uk

http://dx.doi.org/10.1016/j.neuron.2012.09.004



- Auditory Hallucinations in SCZ
- 10Hz-tACS/tDCS/placebo (double blind)
- 20 min bid / 5 days
- 24 pts
- Primary: AHRS
- Target Engagement: hdEEG






Angel Peterchev

- Major depressive disorder
- 10Hz-tACS/40Hz-tACS/placebo (double blind)
- 40 min qd / 5 days
- 30 pts
- Primary: MADRS (4 week follow up)
- Target Engagement: hdEEG

Our Experience


Safety
Feasibility
Technology


Stimulation Questionnaire Results



Device Technology

Safety
Placebo Stimulation
Effective Blinding
Quality Control





The Future?

...is here?





Premenstrual dysphoric disorder (crossover, 10Hz tACS, placebo).




Post-traumatic stress disorder (10Hz tACS, placebo).



























Maternal immune activation: Implications for neuropsychiatric disorders

Myka L. Estes and A. Kimberley McAllister*

Epidemiological evidence implicates maternal infection as a risk factor for autism spectrum disorder and schizophrenia. Animal models corroborate this link and demonstrate that maternal immune activation (MIA) alone is sufficient to impart lifelong neuropathology and altered behaviors





Fig. 1. MIA as a disease primer. This schematic depicts the current model for how MIA leads to psychiatric disorders in offspring. Infection leads to release of proinflammatory cytokines and activation of T_H17 cells in the mother's bloodstream (6, 19). A combination of genetic background, autoimmune status, and second hits during childhood and adolescence (including stress and drug abuse) combines with the consequences of maternal infection to increase the likelihood of offspring developing psychiatric disorders as adults (3, 6, 14, 37).



Negative Valence Systems

Positive Valence Systems

> Cognitive Systems

Social Processes Systems

Arousal & Regulatory Systems Example:

Construct: Acute Threat (Fear)

Domain: Negative Valence Systems

Molecules: Glutamate, Dopamine, Serotonin etc.

Cells: Neurons, Glia, etc.

Circuits: Amygdala, Hippocampus, Hypothalamus, etc.

Physiology: Skin Conductance, Heart Rate, Respiration, etc.

Behavior: Freezing, Avoidance, Response Inhibition etc.

Self-Reports: Fear Questionnaire, Trait Fear Inventory, etc.

Paradigms: Fear conditioning, viewing aversive pictures, etc.

Charles Zhou Caroline Lustenberger Sankar Alagapan Yuhui Li Guoshi Li Ehsan Negahbani Juliann Mellin Courtney Lugo Morgan Alexander Philipp Lustenberger Iain Stitt Supritha Duqyala Toheed Khan Quique Toloza Nadia Mishal Mia DeMarco Matt Mattoni Jhana Parikh Hemanth Ambala Florian Schertenleib Carolyn Rapp Alexandra Vossen Franz Hamilton Jessica Page Maadhurya Duvvuri

Alumni Lab Members Mohsin Ali

Kristin Sellers Katrina Kutchko Stephen Schmidt Chunxiu Yu Carrington Merritt

Collaborators

ECOG: Dr. Haewon Shin Sleep Spindles: Dr. Bradley Vaughn

Modeling ECOG: Dr. Jeremy Lefebvre

Electric Field Spatial Targeting: Dr. Angel Peterchev SCZ Clinical Trial: Dr. Fred Jarskog, Dr. John Gilmore

Mood Disorders Clinical Trials: Dr. David Rubinow

Funding

NIMH BRAINS R01 MH101547, NIMH R21MH105557, NIMH R21MH105574, Human Frontier Science Program, UNC School of Medicine, Department of Psychiatry, NCTraCS (CTSA #1UL1TR001111), Foundation of Hope, UNC SOM TTSA, NARSAD, Tal Medical, Patient Donations.